Relypsa Announces Changes to Board of Directors

  Relypsa Announces Changes to Board of Directors

Business Wire

REDWOOD CITY, Calif. -- January 2, 2013

Relypsa, Inc., a clinical-stage biopharmaceutical company, announced today the
recent appointment of two industry veterans to serve on the company’s board of
directors: Paul J. Hastings, President and CEO of OncoMed Pharmaceuticals, and
David W.J. McGirr, Senior Vice President and Chief Financial Officer of Cubist
Pharmaceuticals.

“Paul and David are widely respected business leaders with broad strategic,
operational and deal-making expertise which will be invaluable as we build
upon our late stage clinical program, gear up to be a commercial stage company
and advance our corporate development strategy,” said Gerrit Klaerner, Ph.D.,
President of Relypsa. “Together they will further diversify the outstanding
talents and wide-ranging experience that our current directors already
provide, bringing new insight and perspectives during this exciting period of
change for the company.”

About Paul J. Hastings

Mr. Hastings is the President and CEO of OncoMed Pharmaceuticals. Prior to
joining OncoMed in 2006, Mr. Hastings was President and Chief Executive
Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and
Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera
Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President
of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that,
he was President and Chief Executive Officer of LXR Biotechnology. Mr.
Hastings also held a series of management positions of increasing
responsibility at Genzyme Corporation, including serving as President of
Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics.
Mr. Hastings also served as Vice President, Marketing and Sales and General
Manager, Europe for Synergen, Inc., and previously held a series of marketing
and sales management positions with Hoffmann-La Roche. Mr. Hastings was
recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in
2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and
Cerimon Pharmaceuticals. He is currently on the board of Pacira
Pharmaceuticals, serves as Chairman of the Emerging Companies Section of the
Biotechnology Industry Organization, and was Chairman of the Bay Area
Biosciences Association (BayBio). Mr. Hastings received a Bachelor of Science
degree in pharmacy from the University of Rhode Island.

About David W.J. McGirr

Mr. McGirr is Senior Vice President and Chief Financial Officer of Cubist
Pharmaceuticals. Prior to joining Cubist in 2002, Mr. McGirr was the President
and Chief Operating Officer of hippo inc, an internet technology,
venture-financed company. Mr. McGirr served as a member of hippo's Board of
Directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB
Robins North America, Inc., a risk management company, serving also as Chief
Executive Officer from 1997 to 1999. Mr. McGirr was a private equity investor
from 1995 to 1996. From 1978 to 1995, Mr. McGirr served in various positions
within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief
Administrative Officer and Managing Director of S.G. Warburg & Co., Inc., a
position held from 1992 to 1995. Mr. McGirr received a B.Sc. in Civil
Engineering from the University of Glasgow and received an M.B.A. from The
Wharton School at the University of Pennsylvania.

About Patiromer and Hyperkalemia

Hyperkalemia is a condition frequently prevalent in patients that suffer from
renal impairment, hypertension, diabetes and/or heart failure. It is
characterized by elevated serum potassium levels, which can lead to cardiac
arrhythmia and sudden death. Patients with chronic kidney disease are at
particular risk for developing hyperkalemia, especially those treated with
renin-angiotensin-aldosterone-system (RAAS) inhibitors. Although RAAS
inhibition has been shown to protect kidney and cardiac function, as well as
prolong life, many patients who could benefit from RAAS inhibitors are
untreated or undertreated due to the undesirable side effect of increasing
serum potassium.

Patiromer (RLY5016) is a high capacity non-absorbed oral potassium binder
being developed for the management of elevated serum potassium levels. Relypsa
has completed several clinical trials of patiromer that have demonstrated the
preliminary efficacy, safety and tolerability of patiromer for the treatment
of hyperkalemia.

About Relypsa, Inc.

Relypsa, Inc. is a late clinical-stage pharmaceutical company leading the
discovery and development of novel non-absorbed polymeric drugs for important
applications in cardiovascular and renal diseases. Relypsa's lead product
candidate is patiromer, a non-absorbed potassium binder for the treatment of
hyperkalemia. Relypsa is pursuing the discovery of additional product
candidates through use of its proprietary polymer platform. More information
is available at www.relypsa.com.

Contact:

Relypsa, Inc.
Kristine Ball, 650-421-9500
SVP, Chief Financial Officer
PR@relypsa.com